Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-18T07:31:39.861Z Has data issue: false hasContentIssue false
  • English
  • Français

A 39-year-old man with a generalized rash with bupropion XL administration

Published online by Cambridge University Press:  16 April 2020

M.A. Ates ,
M. Cetin ,
S. Ebrinc ,
C. Basoglu  and
A. Algul
M.A. Ates
Affiliation:
GATA Haydarpasha Training Hospital, Psychiatry Service, Istanbul, Turkey
M. Cetin
Affiliation:
GATA Haydarpasha Training Hospital, Psychiatry Service, Istanbul, Turkey
S. Ebrinc
Affiliation:
GATA Haydarpasha Training Hospital, Psychiatry Service, Istanbul, Turkey
C. Basoglu
Affiliation:
GATA Haydarpasha Training Hospital, Psychiatry Service, Istanbul, Turkey
A. Algul
Affiliation:
GATA Haydarpasha Training Hospital, Psychiatry Service, Istanbul, Turkey

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

An once-daily formulation, bupropion XL, was developed with the goal of further improving tolerability and compliance (1). Common adverse effects contain dry mouth, nausea, constipation, headache, agitation and skin rash (2).

Objective

A case of skin rash caused by bupropion XL used for depression is discussed.

Results

A 39-year-old man with depression developed a rash on his extremities 13 days after the initiation of bupropion XL followed by pruritus of the arms, feet, and face.

Conclusions

To our knowledge, this is the first reported case of skin rash and urticaria induced by bupropion XL therapy. The most common cutaneous side-effect is urticaria and rash by bupropion XL. This develops from between 8 and 21 days after taking the medicine (3). In our case dermatological side effects developed on 13 days. On discontinuation of bupropion XL, there was whole resolution of symptom. We report this case to notify clinicians of the potential dermatological side effects that can occur with extended release bupropion therapy.

Type
P03-56
Information
European Psychiatry , Volume 26 , Issue S2: Abstracts of the 19th European Congress of Psychiatry , March 2011 , pp. 1225
Copyright
Copyright © European Psychiatric Association 2011

References

Maurizio Fava, et al.15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Prim Care Companion J Clin Psychiatry 2005;7(3)Google Scholar
Dwoskin, Linda P.et al.Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent. CNS Drug Reviews Vol. 12, No: 3–4, 2006 10.1111/j.1527-3458.2006.00178.xCrossRefGoogle ScholarPubMed
Cassis, Tamella B.Callen, Jeffrey P.Bupropion-induced subacute cutaneous lupus rythematosus. Australasian Journal of Dermatology 2005; 46: 266–26910.1111/j.1440-0960.2005.00199.xCrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.